AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7524997 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 167
Study 3035002 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg i.v.)
Number of subjects: 0
Study 3035002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 0
Study 29991053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric Oxyhydroxide
Number of subjects: 68
Study 29991053 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 27185677 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐MAC video laryngoscope
Number of subjects: 140
Study 27185677 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiberoptic scope (FFS)
Number of subjects: 140
Study 25602163 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-5214 (dexmecamylamine) adjunct therapy (0.5, 2 or 4 mg in Study 004; 0.1, 1 or 4 mg in Study 005)
Number of subjects: 1336
Study 25602163 — intervention group
Group type: COMPARATOR
Intervention: Placebo adjunct therapy
Number of subjects: 1336
Study 24006670 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) combined with target controlled infusion of Propofol
Number of subjects: 40
Study 24006670 — intervention group
Group type: COMPARATOR
Intervention: Control group (target controlled infusion of Propofol without TAES)
Number of subjects: 40
Study 21911122 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic bilateral nephrectomy (LBN)
Number of subjects: 66
Study 21911122 — intervention group
Group type: COMPARATOR
Intervention: Open bilateral nephrectomy (OBN)
Number of subjects: 66
Study 18628529 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 20
Study 18628529 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 20
Study 17029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study 17029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad
Number of subjects: 0
Study 17029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Other therapies (hemodynamic maneuvers, magnesium, statins, endothelin antagonists, steroid drugs, anticoagulant/antiplatelet agents, intrathecal fibrinolytic drugs)
Number of subjects: 0
Study 17029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (nicardipine)
Number of subjects: 0
Study 17029347 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue therapy (balloon angioplasty, intraarterial vasodilating agents)
Number of subjects: 0
Study 12870775 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meals
Number of subjects: 251
Study 12870775 — intervention group
Group type: COMPARATOR
Intervention: Solid meals
Number of subjects: 251
Study 10587835 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient diabetes care management delivered by a diabetes nurse educator, psychologist, nutritionist, and pharmacist in cluster visit settings for 6 months.
Number of subjects: 0
Study 10587835 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 8598090 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided mapping (group 2B)
Number of subjects: 89
Study 8598090 — intervention group
Group type: COMPARATOR
Intervention: Standard mapping (group 2A)
Number of subjects: 89
Study 8598090 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 89
Study 1928658 — intervention group
Group type: EXPERIMENTAL
Intervention: SR 2640
Number of subjects: 9
Study 1928658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6614279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental setting
Number of subjects: 60
Study 6614279 — intervention group
Group type: COMPARATOR
Intervention: Medical setting
Number of subjects: 60
Study 31604630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation
Number of subjects: 0
Study 31604630 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure
Number of subjects: 0
Study 28766740 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning
Number of subjects: 12
Study 28766740 — intervention group
Group type: COMPARATOR
Intervention: Traditional PowerPoint learning
Number of subjects: 12
Study 27253231 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour infusion of 20 mg nafamostat mesilate
Number of subjects: 382
Study 27253231 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour infusion of 20 mg nafamostat mesilate
Number of subjects: 382
Study 27253231 — intervention group
Group type: COMPARATOR
Intervention: Control group (6-hour infusion)
Number of subjects: 382
Study 24382719 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation program with early range of motion
Number of subjects: 124
Study 24382719 — intervention group
Group type: COMPARATOR
Intervention: Immobilization group with delayed range of motion for six weeks
Number of subjects: 124
Study 24382719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rehabilitation protocols
Number of subjects: 124
Study 21847539 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amitriptyline, ketamine, and lidocaine (AKL) applied three times a day until 2 weeks post-radiotherapy.
Number of subjects: 16
Study 21106059 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments
Number of subjects: 281
Study 21106059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 18201610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase (75 turbidity‐reducing units)
Number of subjects: 20
Study 18201610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15977132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix of attributes approach (experimental group)
Number of subjects: 140
Study 15977132 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 12563136 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 56
Study 12563136 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 56
Study 10882317 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP)
Number of subjects: 121
Study 10882317 — intervention group
Group type: COMPARATOR
Intervention: Traditional Public Health Nursing (TPHN)
Number of subjects: 121
Study 8771420 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopy combined with endoscopic therapy for patients with bloody aspirate
Number of subjects: 325
Study 8771420 — intervention group
Group type: COMPARATOR
Intervention: Delayed endoscopy for patients with clear or coffee-grounds aspirate
Number of subjects: 325
Study 1466212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (1 mg.kg‐1)
Number of subjects: 200
Study 1466212 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 200
Study 2582377 — intervention group
Group type: EXPERIMENTAL
Intervention: RS4
Number of subjects: 19
Study 2582377 — intervention group
Group type: EXPERIMENTAL
Intervention: TX
Number of subjects: 19
Study 31897406 — intervention group
Group type: EXPERIMENTAL
Intervention: Henna oil
Number of subjects: 108
Study 31897406 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 108
Study 31897406 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 29331381 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate (AA) or enzalutamide (E) after ADT alone
Number of subjects: 102
Study 29331381 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) or enzalutamide (E) after ADT+D
Number of subjects: 102
Study 27736198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrostomy drainage (Group 1: 8F or 10F)
Number of subjects: 30
Study 27736198 — intervention group
Group type: COMPARATOR
Intervention: Ureteral stent (Group 2)
Number of subjects: 30
Study 25295434 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized treatment (CAU + PEP + psychiatric consultation or cognitive‐behavioral therapy)
Number of subjects: 146
Study 25295434 — intervention group
Group type: COMPARATOR
Intervention: Primary treatment (CAU or CAU + PEP)
Number of subjects: 146
Study 21742445 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment + naltrexone
Number of subjects: 40
Study 21742445 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 20675864 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy laser therapy (Group A, n=35)
Number of subjects: 94
Study 20675864 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum therapy combined with Ultra Reiz current (Group C, n=32)
Number of subjects: 94
Study 20675864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (Group B, n=27)
Number of subjects: 94
Study 18207595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20
Study 18207595 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study 15749735 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (80 mg kg(‐1) followed by infusion at 2 g h(‐1))
Number of subjects: 9
Study 15749735 — intervention group
Group type: COMPARATOR
Intervention: Control (no magnesium)
Number of subjects: 9
Study 12884643 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (specific type not mentioned, but atorvastatin is referenced for cost comparison)
Number of subjects: 0
Study 12884643 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study 10640259 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg zolmitriptan
Number of subjects: 49784
Study 10640259 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan
Number of subjects: 49784
Study 8876359 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine pranobex (1 g orally 3 times a day for 6 weeks)
Number of subjects: 55
Study 8876359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2054277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 2054277 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 6696302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxacillin 500 mg qid for five days
Number of subjects: 11
Study 6696302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31314106 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation Injury (INHI)
Number of subjects: 345
Study 31314106 — intervention group
Group type: COMPARATOR
Intervention: No Inhalation Injury (No INHI)
Number of subjects: 345
Study 31314106 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 345
Study 28699267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat 1,000 mg b.i.d. for 12 weeks
Number of subjects: 10
Study 28699267 — intervention group
Group type: COMPARATOR
Intervention: Enzyme Replacement Therapy (ERT) only
Number of subjects: 10
Study 26758265 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery (arthroscopic debridement and partial resection of degenerative knee tissues) in addition to optimised non-operative therapy
Number of subjects: 168
Study 26758265 — intervention group
Group type: COMPARATOR
Intervention: Optimised non-operative therapy only
Number of subjects: 168
Study 24022643 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5 % solution
Number of subjects: 80
Study 24022643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide 250 mg/day
Number of subjects: 80
Study 24022643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no agent)
Number of subjects: 80
Study 22231571 — intervention group
Group type: EXPERIMENTAL
Intervention: Night splinting
Number of subjects: 20
Study 22231571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve and tendon gliding exercises
Number of subjects: 20
Study 22231571 — intervention group
Group type: COMPARATOR
Intervention: Advice to remain active
Number of subjects: 20
Study 20669670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginaton 1 mg/kg
Number of subjects: 60
Study 20669670 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study 17505565 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (PPI, clarithromycin, amoxicillin)
Number of subjects: 17
Study 17505565 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (PPI, clarithromycin, metronidazole)
Number of subjects: 17
Study 17505565 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (PPI, amoxicillin, metronidazole)
Number of subjects: 17
Study 17505565 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (PPI, bismuth, metronidazole, tetracycline) for 7-10 days
Number of subjects: 17
Study 17492326 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 395
Study 15017231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque electromotive administration of 5 mg verapamil and 8 mg dexamethasone
Number of subjects: 96
Study 15017231 — intervention group
Group type: COMPARATOR
Intervention: Electromotive administration of 2% lidocaine
Number of subjects: 96
Study 11386773 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic interposition arthroplasty with crossed intrinsic transfer
Number of subjects: 36
Study 11386773 — intervention group
Group type: COMPARATOR
Intervention: Silastic interposition arthroplasty without crossed intrinsic transfer
Number of subjects: 36
Study 9241405 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenylalanine supplement over 3 months
Number of subjects: 16
Study 9241405 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 16
Study 8257482 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation
Number of subjects: 4156
Study 8257482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin I‐II sample
Number of subjects: 4156
Study 8257482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined trace element I‐II sample
Number of subjects: 4156
Study 8257482 — intervention group
Group type: EXPERIMENTAL
Intervention: Total trace element sample
Number of subjects: 4156
Study 8257482 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vitamin sample
Number of subjects: 4156
Study 3329102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg/day before breakfast for six months
Number of subjects: 19
Study 3329102 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day before breakfast for six months
Number of subjects: 19
Study 3329102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg/day before breakfast from 7th to 12th month
Number of subjects: 19
Study 30975666 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical coaching (TMC)
Number of subjects: 104
Study 30975666 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (C1)
Number of subjects: 104
Study 30975666 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (C2)
Number of subjects: 104
Study 30975666 — intervention group
Group type: COMPARATOR
Intervention: All groups (including TMC, C1, C2)
Number of subjects: 104
Study 28689608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Adults (CM)
Number of subjects: 332
Study 25726558 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team (MDT) approach in diagnosis of IPF
Number of subjects: 0
Study 24169422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to alleviate effects of the initial interview
Number of subjects: 0
Study 24169422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to enhance effects of the initial interview
Number of subjects: 0
Study 24169422 — intervention group
Group type: COMPARATOR
Intervention: Initial interview discussing a distressing event
Number of subjects: 0
Study 21539403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of lisdexamfetamine dimesylate 50 mg
Number of subjects: 18
Study 21539403 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of lisdexamfetamine dimesylate 50 mg
Number of subjects: 18
Study 19359665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 21
Study 19359665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19359665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin with caffeine
Number of subjects: 21
Study 17042717 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg daily
Number of subjects: 5596
Study 17042717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5596
Study 15250197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongfengkang (TFK)
Number of subjects: 40
Study 15250197 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin and Allopurinol (Control)
Number of subjects: 40
Study 12474071 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye and orange juice group (33 volunteers)
Number of subjects: 64
Study 12474071 — intervention group
Group type: COMPARATOR
Intervention: Fortified wheat bread and apple juice group (31 volunteers)
Number of subjects: 64
Study 9664993 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine and azathioprine (group A)
Number of subjects: 27
Study 9664993 — intervention group
Group type: COMPARATOR
Intervention: prednisone, cyclosporine, and azathioprine (group B)
Number of subjects: 27
Study 8566979 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% cream
Number of subjects: 90
Study 8566979 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% cream
Number of subjects: 90
Study 8566979 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% solution
Number of subjects: 90
Study 2528439 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/potassium hydroxyquinoline sulphate cream with hydrocortisone
Number of subjects: 107
Study 2528439 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide/potassium hydroxyquinoline sulphate cream without hydrocortisone
Number of subjects: 107
Study 2528439 — intervention group
Group type: COMPARATOR
Intervention: Aqueous astringent cream base alone
Number of subjects: 107
Study 2528439 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide alcoholic gel
Number of subjects: 107
Study 4911743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenoxylate hydrochloride
Number of subjects: 45
Study 30596467 — intervention group
Group type: EXPERIMENTAL
Intervention: B-APQ
Number of subjects: 0
Study 30596467 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of chronic illness
Number of subjects: 0
Study 30843602 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-leg (blood flow restriction; pressure: ∼180 mmHg)
Number of subjects: 10
Study 30843602 — intervention group
Group type: COMPARATOR
Intervention: CON-leg (control leg, trained without BFR)
Number of subjects: 10
Study 27917462 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously transfused patients
Number of subjects: 166
Study 27917462 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomised patients
Number of subjects: 166
Study 27917462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with saturated transferrin
Number of subjects: 166
Study 27917462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with >20 prior transfusions
Number of subjects: 166
Study 27917462 — intervention group
Group type: EXPERIMENTAL
Intervention: NTDT patients with TfSat >70%
Number of subjects: 166
Study 26031204 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of five warming devices (Azuki no Chikara, Eye Hot R, hot towel, Hot Eye Mask, Memoto Este)
Number of subjects: 20
Study 26031204 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated application of Azuki no Chikara (non‐wet device)
Number of subjects: 20
Study 23562353 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA copy number levels and mRNA expression
Number of subjects: 251
Study 23562353 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression and protein expression
Number of subjects: 251
Study 23562353 — intervention group
Group type: EXPERIMENTAL
Intervention: Copy number levels and mRNA expression
Number of subjects: 251
Study 23562353 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall expression of cyclin B1
Number of subjects: 251
Study 23562353 — intervention group
Group type: EXPERIMENTAL
Intervention: hsa-miR-29c
Number of subjects: 251
Study 23562353 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNB1 copy number
Number of subjects: 251
Study 23562353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin B1 copy number aberrations
Number of subjects: 251
Study 21927856 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (200 ml h(‐1) of a mixture of 18 amino acids)
Number of subjects: 22
Study 21927856 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (200 ml h(‐1))
Number of subjects: 22
Study 21927856 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 22
Study 21927856 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 22
Study 21927856 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion and saline infusion
Number of subjects: 22
Study 19395954 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated reperfusion network
Number of subjects: 0
Study 19395954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis, facilitated PCI, prompt transfer to institutions with primary PCI capabilities
Number of subjects: 0
Study 16122784 — intervention group
Group type: EXPERIMENTAL
Intervention: EBS Multi/Compolute (3M Espe)
Number of subjects: 31
Study 16122784 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac/Variolink II low (Ivoclar Vivadent)
Number of subjects: 31
Study 16122784 — intervention group
Group type: COMPARATOR
Intervention: Both adhesives
Number of subjects: 31
Study 16618688 — intervention group
Group type: EXPERIMENTAL
Intervention: Education/orientation program
Number of subjects: 0
Study 11682389 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation with BIS target of 75
Number of subjects: 30